These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 20412543)

  • 1. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group.
    Guo JJ; Pandey S; Doyle J; Bian B; Lis Y; Raisch DW
    Value Health; 2010 Aug; 13(5):657-66. PubMed ID: 20412543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis.
    Garrison LP; Towse A; Bresnahan BW
    Health Aff (Millwood); 2007; 26(3):684-95. PubMed ID: 17485745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
    Leong J; McAuslane N; Walker S; Salek S
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):1004-12. PubMed ID: 23740622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of PKPD relationships into benefit-risk analysis.
    Bellanti F; van Wijk RC; Danhof M; Della Pasqua O
    Br J Clin Pharmacol; 2015 Nov; 80(5):979-91. PubMed ID: 25940398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two approaches to incorporate clinical data uncertainty into multiple criteria decision analysis for benefit-risk assessment of medicinal products.
    Wen S; Zhang L; Yang B
    Value Health; 2014 Jul; 17(5):619-28. PubMed ID: 25128056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory requirements and optimization of multiple criteria decision analysis to quantify the benefit-risk assessment of medical devices.
    Su G; Deng D
    Expert Rev Med Devices; 2023 Apr; 20(4):273-281. PubMed ID: 36896851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The identification of benefit in medical intervention: an overview and suggestions for process.
    Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
    Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
    Maro JC; Brown JS
    Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Food safety: risk assessment methodology and decision-making criteria.
    Brock WJ; Rodricks JV; Rulis A; Dellarco VL; Gray GM; Lane RW
    Int J Toxicol; 2003; 22(6):435-51. PubMed ID: 14680991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case study using the PrOACT-URL and BRAT frameworks for structured benefit risk assessment.
    Nixon R; Dierig C; Mt-Isa S; Stöckert I; Tong T; Kuhls S; Hodgson G; Pears J; Waddingham E; Hockley K; Thomson A
    Biom J; 2016 Jan; 58(1):8-27. PubMed ID: 25619173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structured Benefit-risk assessment: a review of key publications and initiatives on frameworks and methodologies.
    Mt-Isa S; Ouwens M; Robert V; Gebel M; Schacht A; Hirsch I
    Pharm Stat; 2016 Jul; 15(4):324-32. PubMed ID: 25981683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study.
    Gagne JJ; Najafzadeh M; Choudhry NK; Bykov K; Kahler KH; Martin D; Rogers JR; Schneeweiss S
    Value Health; 2015 Dec; 18(8):1057-62. PubMed ID: 26686791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive approach to benefit-risk assessment in drug development.
    Sarac SB; Rasmussen CH; Rasmussen MA; Hallgreen CE; Søeborg T; Colding-Jørgensen M; Christensen PK; Thirstrup S; Mosekilde E
    Basic Clin Pharmacol Toxicol; 2012 Jul; 111(1):65-72. PubMed ID: 22356197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework.
    Angelis A; Kanavos P
    Soc Sci Med; 2017 Sep; 188():137-156. PubMed ID: 28772164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature.
    Kürzinger ML; Douarin L; Uzun I; El-Haddad C; Hurst W; Juhaeri J; Tcherny-Lessenot S
    Ther Adv Drug Saf; 2020; 11():2042098620976951. PubMed ID: 33343857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
    Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
    Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis.
    Mussen F; Salek S; Walker S
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S2-S15. PubMed ID: 17546573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit-risk analysis : a brief review and proposed quantitative approaches.
    Holden WL
    Drug Saf; 2003; 26(12):853-62. PubMed ID: 12959629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome.
    Lynd LD; Najafzadeh M; Colley L; Byrne MF; Willan AR; Sculpher MJ; Johnson FR; Hauber AB
    Value Health; 2010; 13(4):411-7. PubMed ID: 19744297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.